Print this page    •   Back to Web version of article

Medical News
Vertex Drug Promising in Hepatitis C Patients With HIV

March 7, 2011

Substantially more HIV/hepatitis C virus co-infected patients taking the investigational HCV drug telaprevir achieved a rapid viral response (RVR) than those taking standard therapy alone, researchers reported at the 18th Conference on Retroviruses and Opportunistic Infections in Boston. RVR, defined as undetectable HCV after four weeks of treatment, can be an early indicator of eventually attaining a sustained viral response (SVR).


In previous trials, telaprevir has improved rates of SVR when used in combination with pegylated interferon and ribavirin. Vertex Pharmaceuticals Inc.'s drug is awaiting approval by the Food and Drug Administration.

The small, mid-stage trial presented at the conference involved 60 hepatitis C patients co-infected with HIV who were either taking antiretroviral therapy or not (non-ARV).

At four weeks, 70 percent taking combination HCV therapy with telaprevir achieved RVR, compared with just 5 percent on standard HCV therapy. Of patients taking Atripla, 75 percent achieved RVR on the telaprevir combination, versus one patient (12.5 percent) in the control arm. Of HIV patients taking Reyataz, 64 percent had RVR and no one did in the control arm. In non-ARV patients, 71 percent in the telaprevir group achieved RVR compared with none on standard therapy.

SVR data are expected next year, Vertex said.

Back to other news for March 2011

Excerpted from:
03.02.2011; Bill Berkrot

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.